logo

COVID-19: Drugs in Development

Share

The COVID-19 outbreak, which started in December 2019 in Wuhan City, China, was declared a "Public Health Emergency of International Concern" by the WHO on January 30, 2020. The outbreak was characterized as a pandemic on March 11, 2020.

Currently, there are no drugs to treat COVID-19, caused by the novel coronavirus SARS-CoV-2.

Listed below are companies that are in the race to find a treatment or vaccine for the novel coronavirus.

Subscribe to RTT Intelligent Investor for FREE 7-Day Trial with complete access to COVID-19 Drugs in Development Calendar.

Company Name
Drug
Current Stage
Next Milestone
Collaboration
Last Updated
Aluda Pharmaceuticals
ALD-R491
Research
-
-
10/14/2021
60 Degrees Pharmaceuticals, LLC
ARAKODA (tafenoquine)
On Oct. 12, 2021, DSMB recommended continuation of Phase 2 study of ARAKODA for the treatment of mild-moderate COVID-19 in adults.
-
-
10/13/2021
Covicept Therapeutics
PJS-539
On October 06, 2021, initiated Phase 2 study of PJS-539 for the treatment of patients with COVID-19.
-
-
10/06/2021
CTI BioPharma Corp.
(CTIC)
Pacritinib
Phase 3 study of Pacritinib in hospitalized patients with severe COVID-19 (PRE-VENT).
--On Oct.1, 2021, the company announced it is discontinuing further development of pacritinib for the treatment of severe COVID-19 as it did not show any clinical benefit
-
-
10/04/2021
VBI Vaccines Inc.
(VBIV)
Covid-19 Vaccines
On Sept, 29, 2021, positive results from multiple preclinical studies against several COVID-19 variants of concern were reported. Also, initiated Phase 1b portion of the ongoing study of VBI’s SARS-CoV-2 vaccine candidates.
-
-
09/30/2021
AB Science SA
Masitinib
On Sept.28, 2021, received clearance from regulatory authorities of Russia and South Africa for a second Phase 2 study dubbed AB21002 of masitinib, in patients with symptomatic mild and moderate COVID-19.
-
-
09/29/2021
Reven Holdings, Inc.
RJX
On Sept.24,2021, successfully completed part 1 of the two-part, Phase 1/2 study of RJX in hospitalized high-risk COVID-19 patients. DSMB approved initiation of part 2 portion of the Phase 2 study.
-
-
09/27/2021
Pulmotect, Inc.
PUL-042
On Sept.24,2021, positive topline results from the first two Phase 2 studies of PUL-042 for the treatment of Covid-19 were reported.
-
US Department of Defense (DOD)
09/27/2021

Get Full Access to latest records of COVID-19 Drugs in Development Calendar by subscribing to RTT Intelligent Investor with FREE 7-Day Trial. (No Credit Card Required)

Editors Pick
e-Commerce giant Amazon is set to hire 150,000 seasonal employees across the U.S. to manage the upcoming holiday season better. It is looking to provide seasonal jobs to people of all backgrounds and skill levels. Amazon noted that all jobs in the U.S., including seasonal roles, have an average starting pay of $18 per hour, sign-on bonuses up to $3,000 and an additional $3 per hour based on shifts Facebook is planning to create 10,000 new high-skilled jobs within the European Union over the next five years to help build the metaverse, a new concept of a digital world. Metaverse is described as a new phase of interconnected virtual experiences using technologies like virtual and augmented reality. In a blog post, the company stated that the metaverse has the potential to help unlock access.. Walmart is bringing back its month-long savings event "Black Friday Deals for Days" in November, with special early access for Walmart+ members. The retail behemoth, which reinvented the Black Friday shopping events last year, will spread out its Black Friday savings to three events throughout November. Each savings event will begin online at Walmart.com and continue with the same deals in stores.